You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 10,111,900

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,111,900

Title:	.beta.-glucan methods and compositions that affect the tumor microenvironment
Abstract:	This disclosure relates to the combination of soluble .beta.-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble .beta.-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.
Inventor(s):	Bose; Nandita (Plymouth, MN), Gorden; Keith (Woodbury, MN), Chan; Anissa Sh. (Arden Hills, MN), Leonardo; Steven (Rosemount, MN), Graff; Jeremy (Indianapolis, IN), Qiu; Xiaohong (Edina, MN), Kangas; Takashi (Shoreview, MN), Fraser; Kathryn A. (St. Paul, MN), Bykowski Jonas; Adria (Eden Prairie, MN), Ottoson; Nadine (Lakeville, MN), Fulton; Ross (St. Paul, MN)
Assignee:	BIOTHERA, INC. (Eagan, MN)
Application Number:	15/386,781
Patent Claims:	1. A method of treating a subject having cancer, the method comprising administering soluble .beta.(1,6)-[poly-(1,3)-D-glucopyranosyl]-poly-.beta.(1,3)-D-glucopyranos- e and an anti-PD-1 antibody. 2. The method according to claim 1, wherein the cancer is melanoma, renal cell carcinoma, or lung cancer. 3. The method according to claim 1, wherein the cancer is breast cancer, pancreatic cancer, colon cancer, or B cell lymphoma. 4. The method according to claim 1, wherein the .beta.(1,6)-[poly-(1,3)-D-glucopyranosyl]-poly-.beta.(1,3)-D-glucopyranos- e and the anti-PD-1 antibody are in a single formulation. 5. The method according to claim 1, wherein the .beta.(1,6)-[poly-(1,3)-D-glucopyranosyl]-poly-.beta.(1,3)-D-glucopyranos- e and the anti-PD-1 antibody are in separate formulations. 6. The method according to claim 1, wherein the .beta.(1,6)-[poly-(1,3)-D-glucopyranosyl]-poly-.beta.(1,3)-D-glucopyranos- e is derived from yeast. 7. The method according to claim 6, wherein the yeast is Saccharomyces cerevisiae. 8. The method according to claim 1, wherein the .beta.(1,6)-[poly-(1,3)-D-glucopyranosyl]-poly-.beta.(1,3)-D-glucopyranos- e stimulates the subject's immune system. 9. The method according to claim 1, wherein the anti-PD-1 antibody is a non-complement-activating antibody. 10. The method according to claim 1, wherein the anti-PD-1 antibody is a complement-activating antibody. 11. The method according to claim 1, wherein the anti-PD-1 antibody is an IgG.sub.4 antibody. 12. The method according to claim 1, wherein the anti-PD-1 antibody is nivolumab or pembrolizumab. 13. The method according to claim 1, wherein the method further comprises administering bavituximab, ipilimumab, or tremelimumab. 14. The method according to claim 1, wherein the method further comprises administration of a tumor targeting antibody. 15. The method according to claim 1, wherein the method does not include IL-2 administration. 16. A method of stimulating a subject's immune system against cancer cells, the method comprising administering soluble .beta.(1,6)-[poly-(1,3)-D-glucopyranosyl]-poly-.beta.(1,3)-D-glucopyranos- e and an anti-PD-1 antibody. 17. The method according to claim 16, wherein the immune stimulation comprises activation of M1 macrophages, N1 neutrophils, NK cells, T cells, B cells or dendritic cells. 18. The method according to claim 16, wherein the immune stimulation comprises activation of interleukin-12, interferon-.gamma., tumor-necrosis factor .alpha., or a combination thereof. 19. A method of removing immune suppression in a tumor microenvironment, the method comprising administering soluble .beta.(1,6)-[poly-(1,3)-D-glucopyranosyl]-poly-.beta.(1,3)-D-glucopyranos- e and an anti-PD-1 antibody. 20. The method according to claim 19, wherein the method comprises suppression of M2 macrophages, N2 neutrophils, myeloid-derived suppressor cells, or a combination thereof.

Details for Patent 10,111,900

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	YERVOY	ipilimumab	Injection	125377	03/25/2011	⤷ Try a Trial	2034-11-06
Merck Sharp & Dohme Corp.	KEYTRUDA	pembrolizumab	For Injection	125514	09/04/2014	⤷ Try a Trial	2034-11-06
Merck Sharp & Dohme Corp.	KEYTRUDA	pembrolizumab	Injection	125514	01/15/2015	⤷ Try a Trial	2034-11-06
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	12/22/2014	⤷ Try a Trial	2034-11-06
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	10/04/2017	⤷ Try a Trial	2034-11-06
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	08/27/2021	⤷ Try a Trial	2034-11-06
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.